Damora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(209,839) | $(21,439) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Depreciation of equipment | 22 | 21 |
| Stock-based compensation | 998 | 3,239 |
| Issuance of common stock in connection with vesting of restricted stock units | 39 | 93 |
| Issuance of preferred and common stock in connection with an Asset Purchase Agreement | — | 1,890 |
| In-process research and development costs in connection with Damora Asset Acquisition | 174,310 | — |
| Issuance of Paramora Warrant, net of cost assumed in Damora Asset Acquisition | 9,362 | — |
| Amortization of premiums and discounts on marketable securities | — | 70 |
| Amortization of right of use lease asset | 12 | 160 |
| Accretion of lease liability | 6 | 10 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (138) | 954 |
| Other assets, noncurrent | 166 | 970 |
| Accounts payable | 51 | (1,325) |
| Accrued expenses and other current liabilities | 1,099 | (3,139) |
| Related party accounts payable and other current liabilities | 17,221 | — |
| Operating lease liabilities | (20) | (170) |
| Other liabilities, noncurrent | (15) | 43 |
| Net cash used in operating activities | (6,726) | (18,623) |
| Cash flows from investing activities | ||
| Damora Asset Acquisition costs, net of cash assumed | (17,374) | — |
| Proceeds from sale of marketable securities | — | 11,650 |
| Net cash (used in) provided by investing activities | (17,374) | 11,650 |
| Cash flows from financing activities | ||
| Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs | 266,811 | — |
| Proceeds from issuance of common stock in connection with stock option exercise | 33 | — |
| Net cash provided by financing activities | 266,844 | — |
| Net increase (decrease) in cash and cash equivalents | 242,744 | (6,973) |
| Effect of exchange rate changes on cash and cash equivalents | 705 | (317) |
| Cash and cash equivalents, beginning of year | 14,175 | 21,465 |
| Cash and cash equivalents, end of year | $257,624 | $14,175 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for taxes | $5 | $— |
| Supplemental disclosures of noncash activities: | ||
| Fair value of the Series B Preferred Stock issued in connection with the Damora Asset Acquisition | $152,677 | $— |
| Operating lease liability arising from obtaining right-of-use assets | $— | $75 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.